vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and i3 Verticals, Inc. (IIIV). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($71.7M vs $52.7M, roughly 1.4× i3 Verticals, Inc.). i3 Verticals, Inc. runs the higher net margin — 0.9% vs -18.9%, a 19.9% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (51.0% vs -14.6%). i3 Verticals, Inc. produced more free cash flow last quarter ($13.8M vs $1.4M). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (30.8% CAGR vs -4.7%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
The Prusa i3 is a family of fused filament fabrication 3D printers, manufactured by Czech company Prusa Research under the trademarked name Original Prusa i3. Part of the RepRap project, Prusa i3 printers were called the most used 3D printer in the world in 2016. The first Prusa i3 was designed by Josef Průša in 2012, and was released as a commercial kit product in 2015. The latest model is available in both kit and factory assembled versions. The Prusa i3's comparable low cost and ease of co...
ADPT vs IIIV — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $52.7M |
| Net Profit | $-13.6M | $484.0K |
| Gross Margin | 74.6% | — |
| Operating Margin | -17.8% | 3.1% |
| Net Margin | -18.9% | 0.9% |
| Revenue YoY | 51.0% | -14.6% |
| Net Profit YoY | 59.7% | -76.5% |
| EPS (diluted) | $-0.08 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | $52.7M | ||
| Q3 25 | $94.0M | $46.0M | ||
| Q2 25 | $58.9M | $51.9M | ||
| Q1 25 | $52.4M | $63.1M | ||
| Q4 24 | $47.5M | $52.2M | ||
| Q3 24 | $46.4M | $32.0M | ||
| Q2 24 | $43.2M | $46.2M | ||
| Q1 24 | $41.9M | $58.0M |
| Q4 25 | $-13.6M | $484.0K | ||
| Q3 25 | $9.5M | $3.1M | ||
| Q2 25 | $-25.6M | $12.9M | ||
| Q1 25 | $-29.9M | $-154.0K | ||
| Q4 24 | $-33.7M | $2.1M | ||
| Q3 24 | $-32.1M | $117.9M | ||
| Q2 24 | $-46.2M | $-7.5M | ||
| Q1 24 | $-47.5M | $1.9M |
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
| Q4 25 | -17.8% | 3.1% | ||
| Q3 25 | 10.9% | 3.2% | ||
| Q2 25 | -42.5% | -9.3% | ||
| Q1 25 | -56.4% | 8.0% | ||
| Q4 24 | -71.3% | 3.9% | ||
| Q3 24 | -70.3% | 10.6% | ||
| Q2 24 | -109.6% | -2.8% | ||
| Q1 24 | -116.5% | 3.4% |
| Q4 25 | -18.9% | 0.9% | ||
| Q3 25 | 10.2% | 6.7% | ||
| Q2 25 | -43.5% | 24.8% | ||
| Q1 25 | -56.9% | -0.2% | ||
| Q4 24 | -71.0% | 3.9% | ||
| Q3 24 | -69.1% | 368.2% | ||
| Q2 24 | -107.0% | -16.3% | ||
| Q1 24 | -113.5% | 3.2% |
| Q4 25 | $-0.08 | $0.02 | ||
| Q3 25 | $0.06 | $0.14 | ||
| Q2 25 | $-0.17 | $0.50 | ||
| Q1 25 | $-0.20 | $0.00 | ||
| Q4 24 | $-0.22 | $0.08 | ||
| Q3 24 | $-0.22 | $4.93 | ||
| Q2 24 | $-0.31 | $-0.32 | ||
| Q1 24 | $-0.33 | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $37.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $218.8M | $358.5M |
| Total Assets | $512.7M | $595.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | $37.5M | ||
| Q3 25 | $55.0M | $66.7M | ||
| Q2 25 | $43.2M | $55.5M | ||
| Q1 25 | $50.6M | $7.7M | ||
| Q4 24 | $47.9M | $85.6M | ||
| Q3 24 | $38.1M | $86.5M | ||
| Q2 24 | $59.8M | $9.7M | ||
| Q1 24 | $71.2M | $3.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $12.0M | ||
| Q4 24 | — | $26.2M | ||
| Q3 24 | — | $26.2M | ||
| Q2 24 | — | $374.1M | ||
| Q1 24 | — | $369.6M |
| Q4 25 | $218.8M | $358.5M | ||
| Q3 25 | $204.4M | $389.6M | ||
| Q2 25 | $179.7M | $383.3M | ||
| Q1 25 | $190.4M | $385.2M | ||
| Q4 24 | $202.7M | $375.0M | ||
| Q3 24 | $223.8M | $379.7M | ||
| Q2 24 | $241.6M | $249.7M | ||
| Q1 24 | $274.9M | $249.3M |
| Q4 25 | $512.7M | $595.9M | ||
| Q3 25 | $490.6M | $638.4M | ||
| Q2 25 | $496.6M | $623.3M | ||
| Q1 25 | $510.9M | $646.4M | ||
| Q4 24 | $539.4M | $726.2M | ||
| Q3 24 | $558.5M | $730.7M | ||
| Q2 24 | $584.9M | $861.7M | ||
| Q1 24 | $620.3M | $625.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 1.50× | ||
| Q1 24 | — | 1.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $14.1M |
| Free Cash FlowOCF − Capex | $1.4M | $13.8M |
| FCF MarginFCF / Revenue | 2.0% | 26.2% |
| Capex IntensityCapex / Revenue | 0.9% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 29.18× |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | $6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $14.1M | ||
| Q3 25 | $-7.1M | $14.0M | ||
| Q2 25 | $-12.4M | $7.4M | ||
| Q1 25 | $-28.5M | $-27.1M | ||
| Q4 24 | $-12.5M | $11.5M | ||
| Q3 24 | $-27.1M | $15.1M | ||
| Q2 24 | $-17.3M | $8.1M | ||
| Q1 24 | $-38.4M | $10.7M |
| Q4 25 | $1.4M | $13.8M | ||
| Q3 25 | $-7.5M | $13.5M | ||
| Q2 25 | $-13.1M | $6.8M | ||
| Q1 25 | $-29.7M | $-27.6M | ||
| Q4 24 | $-12.6M | $11.0M | ||
| Q3 24 | $-27.4M | $14.6M | ||
| Q2 24 | $-19.0M | $7.2M | ||
| Q1 24 | $-39.9M | $9.9M |
| Q4 25 | 2.0% | 26.2% | ||
| Q3 25 | -8.0% | 29.5% | ||
| Q2 25 | -22.2% | 13.1% | ||
| Q1 25 | -56.7% | -43.8% | ||
| Q4 24 | -26.5% | 21.1% | ||
| Q3 24 | -59.0% | 45.6% | ||
| Q2 24 | -44.1% | 15.6% | ||
| Q1 24 | -95.2% | 17.1% |
| Q4 25 | 0.9% | 0.6% | ||
| Q3 25 | 0.4% | 0.9% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 2.4% | 0.8% | ||
| Q4 24 | 0.2% | 0.9% | ||
| Q3 24 | 0.7% | 1.7% | ||
| Q2 24 | 4.0% | 1.9% | ||
| Q1 24 | 3.6% | 1.4% |
| Q4 25 | — | 29.18× | ||
| Q3 25 | -0.75× | 4.52× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.59× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 5.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
IIIV
| License And Service | $35.7M | 68% |
| Proprietary Payments Revenue | $14.5M | 27% |
| Other Revenue | $2.5M | 5% |
